Merck & Co., Inc. $MRK Shares Acquired by Resources Management Corp CT ADV

Key Points

• Resources Management Corp CT ADV dramatically boosted its Merck stake by 3,067.4% in the fourth quarter, ending with 59,610 shares valued at about $6.28 million.
• Merck reported better-than-expected quarterly results, with EPS of ($1.28) versus the ($1.47) estimate and revenue of $16.29 billion, while also reaffirming FY 2026 EPS guidance of 5.04 to 5.16.
• The stock continues to draw support from Wall Street and income investors, with a Moderate Buy consensus rating, an average target price of $128.18, and a quarterly dividend of $0.85 per share yielding about 2.9%.

Resources Management Corp CT ADV raised its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 3,067.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,610 shares of the company's stock after purchasing an additional 57,728 shares during the period. Resources Management Corp CT ADV's holdings in Merck & Co., Inc. were worth $6,275,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth $25,000. United Financial Planning Group LLC acquired a new position in shares of Merck & Co., Inc. during the third quarter worth $31,000. High Note Wealth LLC increased its position in shares of Merck & Co., Inc. by 58.9% during the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at $31,000. Finally, Gilpin Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at $32,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $119.05 on Monday. The business's 50-day moving average is $116.55 and its two-hundred day moving average is $113.32. The company has a market capitalization of $294.04 billion, a P/E ratio of 33.54, a P/E/G ratio of 2.68 and a beta of 0.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a fifty-two week low of $76.66 and a fifty-two week high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period last year, the firm earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Research analysts predict that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.'s dividend payout ratio is currently 95.77%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on MRK shares. Zacks Research raised shares of Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 17th. Royal Bank Of Canada reissued an "outperform" rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a report on Monday, March 30th. JPMorgan Chase & Co. boosted their price objective on shares of Merck & Co., Inc. from $125.00 to $135.00 and gave the company an "overweight" rating in a report on Monday, April 6th. UBS Group boosted their price objective on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a "buy" rating in a report on Monday, April 13th. Finally, Citigroup started coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a "neutral" rating and a $125.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Merck & Co., Inc. currently has a consensus rating of "Moderate Buy" and an average target price of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.